Artrya Ltd
ASX:AYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Artrya Ltd
Tax Provision
Artrya Ltd
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Artrya Ltd
ASX:AYA
|
Tax Provision
-AU$29k
|
CAGR 3-Years
62%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
4DMedical Ltd
ASX:4DX
|
Tax Provision
AU$1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CogState Ltd
ASX:CGS
|
Tax Provision
-$3.3m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-86%
|
CAGR 10-Years
N/A
|
|
|
Pro Medicus Ltd
ASX:PME
|
Tax Provision
-AU$98.6m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
-45%
|
|
|
Alcidion Group Ltd
ASX:ALC
|
Tax Provision
AU$885k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
B
|
BlinkLab Ltd
ASX:BB1
|
Tax Provision
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Artrya Ltd
Glance View
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The firm is focused on operating diagnostic imaging center. The company is primarily engaged in providing powered image-analysis software for coronary artery disease. Its non-invasive solution, Salix uses artificial intelligence (AI) to produce a 3D image and report that provides an accurate detection of coronary artery disease, including the presence of vulnerable plaque. Salix offers precision medicine for cardiac care. The company enables clinicians to triage patients and identify individuals at high risk of heart attack. The firm's cardiac-health report provides diagnostic support to radiologists and cardiologists.
See Also
What is Artrya Ltd's Tax Provision?
Tax Provision
-29k
AUD
Based on the financial report for Jun 30, 2025, Artrya Ltd's Tax Provision amounts to -29k AUD.
What is Artrya Ltd's Tax Provision growth rate?
Tax Provision CAGR 3Y
62%
Over the last year, the Tax Provision growth was -7%. The average annual Tax Provision growth rates for Artrya Ltd have been 62% over the past three years .
